Organigram Global Inc. Common Shares (OGI)
OGI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 40-F (ifrs-full:Revenue), fiscal year ended 2025-09-30, https://www.sec.gov/Archives/edgar/data/1620737/000162828025057233/0001628280-25-057233-index.htm. Net income: SEC 40-F (ifrs-full:ProfitLoss), fiscal year ended 2025-09-30. Converted from CAD at 1.4258 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | OGI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001620737 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Canada |
| Canadian listing | TSX: OGI |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $181.8M |
| Net income | -$17.4M |
| Operating income | -$10.7M |
| Net margin | -9.6% |
| Operating margin | -5.9% |
| Revenue growth | +62.2% |
| Cash | $58.6M |
| Total assets | $394.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.6× |
Reported in CAD; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 40-F 2025-12-16 |
| Cash and burn | 83.6M CAD cash; operating cash flow -1.9M CAD a quarter. | Report 2025-09-30 |
| Shares outstanding | 134,461,029 (2025-09-30); 108,585,492 a year earlier. the newest SEC cover-page count is from 2025-09-30; shares issued since then are not in these figures. | Cover page 2025-09-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PKF O'Connor Davies, LLP, New York, New York, United States | PCAOB Form AP 2026-01-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-09-30 | 259.2M CAD | -24.8M CAD | -7.6M CAD | 83.6M CAD | 25K CAD | 259.2M CAD | 40-F 2025-12-16 |
| FY 2025 2024-09-30 | 159.8M CAD | -45.4M CAD | 3.9M CAD | Not filed | 25K CAD | 159.8M CAD | 40-F 2024-12-18 |
| FY 2022 2022-08-31 | 145.8M CAD | -14.3M CAD | -36.2M CAD | Not filed | 235K CAD | 145.8M CAD | 40-F 2023-12-19 |
| FY 2021 2021-08-31 | 79.2M CAD | -130.7M CAD | -28.6M CAD | Not filed | 310K CAD | 79.2M CAD | 40-F 2022-11-29 |
| FY 2020 2020-08-31 | 86.8M CAD | -136.2M CAD | -45.1M CAD | Not filed | 115.3M CAD | 86.8M CAD | 40-F 2021-11-23 |
| FY 2019 2019-08-31 | 80.4M CAD | -9.5M CAD | -35.1M CAD | Not filed | 49.6M CAD | 80.4M CAD | 40-F 2020-11-30 |
| FY 2018 2018-08-31 | 12.4M CAD | 20.5M CAD | -12.7M CAD | Not filed | 3.3M CAD | 12.4M CAD | 40-F/A 2019-12-27 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CAD.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 40-F | 2025-12-16 |
| Latest quarterly / interim | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 324 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.5% |
| 1 month | -9.8% |
| 3 months | -34.2% |
| Year to date | -50.7% |
| 1 year | -46.2% |
| From 52-week high | -60.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CUE | Cue Biopharma Inc. | $14.10 | -12.53% | $102.4M |
| UNCY | Unicycive Therapeutics Inc. | $3.70 | +4.23% | $103.1M |
| ORGO | Organogenesis Holdings Inc. | $0.8031 | -0.86% | $104.2M |
| DERM | Journey Medical Corporation | $3.70 | -14.55% | $104.5M |
| CLLS | Cellectis S.A. | $1.04 | -11.86% | $104.5M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier